Strides Pharma Science stock surges 43.2 percent to 11,294 crore

Market pulse

From the investor's mind

The next leg of growth in the electric vehicle sector may shift away from just delivering better technology toward building platforms that address a much wider customer base. Market commentator Aditya Kondawar highlights how Ather Energy successfully doubled its market share when it introduced the family-oriented Rizta platform. Global brokerage firm JP Morgan expects a similar growth outcome for Ola Electric following the launch of its low-cost EL platform. This transition underscores how targeting broader consumer segments with versatile product architectures is becoming the key catalyst for scaling volumes in India's competitive electric two-wheeler market.

Word in the street

Strides Pharma Science Limited

Investors of Strides Pharma Science Limited have had plenty to discuss as the company stock surged 43.2 percent over the past year, lifting its total market cap to about 11,294 crore. Along with this strong domestic performance, the wider market discussions actively centered on Sandoz recently getting approval for semaglutide in Canada. While there is absolutely no business connection between the Canadian regulatory approval and Strides Pharma Science Limited, both of these independent subjects remained highly talked about. Market participants spent the day analyzing the impressive trajectory of the company alongside these notable global pharmaceutical updates.

Yesterday's big moves

“Always go against the tide. Buy when others are selling and sell when others are buying.”

Rakesh Jhunjhunwala